MARKET RESEARCH TREND

"Peripheral Artery Disease - 5EU China Drug Forecast and Market Analysis to 2024" . The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Summary In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor), and Bayer and Janssens (a subsidiary of Johnson & Johnson) Xarelto (

"Diabetic Peripheral Neuropathy - Pipeline Review, H2 2016" . The Report covers current Market Trends, Analysis, Forecast, Review, Share, Size, Growth, Effect. Description- Summary Diabetic Peripheral Neuropathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Peripheral Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. To Free Sample Report With TOC @ http:/